Outlook Therapeutics Inc (OTLK): Next-Year EPS Estimate 63.54%
As of 2026-07-27, Outlook Therapeutics Inc (OTLK) has a next-year EPS growth estimate of 63.54%. Featured in 4 EPS revision reports, most recently on 2026-06-22.
On 2026-07-27, analyst consensus for OTLK's next-year EPS growth shifted from 46.28% to 63.54% — a positive change of 17.26 percentage points. Current-year growth is projected at 73.18%.
What's Driving This
The primary structural driver for OTLK’s rise is a 17.26 percentage-point upward revision to next-year EPS growth estimates on July 27, 2026, from 46.28% to 63.54%. This upgrade followed the FDA approval of Lytenava (ophthalmic bevacizumab) for wet AMD, a specific product launch catalyst. Since the initial revision, the net EPS estimate has increased by 16.46 percentage points, and the stock continued to gain momentum on upbeat analyst commentary and market enthusiasm for the newly approved therapy.
Generated 2026-07-27 from news as of 2026-07-27
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 63.54%
- EPS growth this year
- 73.18%
- EPS next quarter (est)
- -$0.09
- Last price
- $1.07
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-07-27 | 63.54% | 73.18% | -$0.09 | $1.07 |
| 2026-07-26 | 46.28% | 72.02% | -$0.11 | $1.40 |
| 2026-07-24 | 46.28% | 72.02% | -$0.11 | $1.40 |
| 2026-07-23 | 46.28% | 72.02% | -$0.11 | $1.32 |
| 2026-07-22 | 46.28% | 72.02% | -$0.11 | $1.34 |
| 2026-07-21 | 46.28% | 72.02% | -$0.11 | $1.42 |
| 2026-07-20 | 46.28% | 72.02% | -$0.11 | $1.38 |
| 2026-07-19 | 46.28% | 72.02% | -$0.11 | $1.39 |
| 2026-07-17 | 46.28% | 72.02% | -$0.11 | $1.39 |
| 2026-07-16 | 46.28% | 72.02% | -$0.11 | $1.46 |
| 2026-07-15 | 47.08% | 73.18% | -$0.10 | $1.56 |
| 2026-07-14 | 47.08% | 73.18% | -$0.10 | $1.73 |
| 2026-07-13 | 47.08% | 73.18% | -$0.10 | $1.55 |
| 2026-07-12 | 47.08% | 73.18% | -$0.10 | $1.57 |
| 2026-07-09 | 47.08% | 73.18% | -$0.10 | $1.68 |
| 2026-07-08 | 47.08% | 73.18% | -$0.10 | $1.69 |
| 2026-07-07 | 47.08% | 73.18% | -$0.10 | $1.46 |
| 2026-07-06 | 47.08% | 73.18% | -$0.10 | $1.42 |
| 2026-07-05 | 47.08% | 73.18% | -$0.10 | $1.45 |
| 2026-07-02 | 47.08% | 73.18% | -$0.10 | $1.45 |
| 2026-07-01 | 47.08% | 73.18% | -$0.10 | $1.47 |
| 2026-06-30 | 47.08% | 73.18% | -$0.10 | $1.59 |
| 2026-06-29 | 47.08% | 73.18% | -$0.10 | $1.69 |
| 2026-06-28 | 53.32% | 72.79% | -$0.10 | $1.71 |
| 2026-06-25 | 53.32% | 72.79% | -$0.10 | $1.61 |
| 2026-06-24 | 53.32% | 72.79% | -$0.10 | $1.68 |
| 2026-06-23 | 53.32% | 72.79% | -$0.10 | $1.70 |
| 2026-06-22 | 53.32% | 72.79% | -$0.10 | $1.83 |
| 2026-06-21 | 53.32% | 72.79% | -$0.10 | $1.58 |
| 2026-06-18 | 53.32% | 72.79% | -$0.10 | $1.58 |
Reports Featuring OTLK
- 2026-06-22
Top EPS Revision Winners: OTLK Surges 66%, FTH Gains 60% on Estimate Hikes
- 2026-06-18
OTLK Surges 43.6% on FDA News; WDC +41%, FCEL +37.5% Lead EPS Revision Movers
- 2026-06-17
Outlook Therapeutics Soars 50% as EPS Revision and FDA Acceptance Fuel Rally
- 2026-06-16
OTLK, WDC Lead EPS Revision Winners: +42.7% and +33.1% Gains
Recent News
- Outlook Therapeutics Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIGStocktwits
- Outlook Therapeutics wins FDA approval for Lytenava in wet AMDPharmaceutical Technology
- Outlook Therapeutics shares climb after FDA clears LYTENAVA for wet AMDInvestorsHub
- FDA scientists question Capricor data; Legend CEO steps downBioPharma Dive
- OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug Analysts See Nearly 300% UpsideStocktwits
- FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory DecisionsStocktwits
- OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic BevacizumabStocktwits
- Outlook Therapeutics Announces LYTENAVA FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMDGlobeNewswire
- OTLK Stock Soars 28% After FDA Sets July Date For Lytenava DecisionStocktwits
- Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA (bevacizumab-vikg) as a Treatment for Wet AMDGlobeNewswire
Screen Performance
Aggregate stats across all 1885 tickers our top-EPS-revision screen has flagged over the past 117 days.
- Median return since detection
- +2.2%
- % of tickers in the green
- 55%
- Median return on winners
- +19.3%
- Large revisions captured
- 1125
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Outlook Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-07-27, Outlook Therapeutics Inc (OTLK) has a next-year EPS growth estimate of 63.54%, based on analyst consensus.
When was the latest EPS estimate revision for OTLK?▾
The most recent revision occurred on 2026-07-27, when analysts adjusted the next-year EPS growth estimate from 46.28% to 63.54%.
What sector and industry does Outlook Therapeutics Inc belong to?▾
Outlook Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. OTLK appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Outlook Therapeutics Inc (OTLK) appears here because it was detected by our daily top-EPS-revision-performer screen.